JP7115756B2 - ヒトの皮膚の老化の新規バイオマーカー - Google Patents

ヒトの皮膚の老化の新規バイオマーカー Download PDF

Info

Publication number
JP7115756B2
JP7115756B2 JP2019528092A JP2019528092A JP7115756B2 JP 7115756 B2 JP7115756 B2 JP 7115756B2 JP 2019528092 A JP2019528092 A JP 2019528092A JP 2019528092 A JP2019528092 A JP 2019528092A JP 7115756 B2 JP7115756 B2 JP 7115756B2
Authority
JP
Japan
Prior art keywords
protein
skin
gene
expression level
hmga2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2019528092A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502498A5 (https=
JP2020502498A (ja
Inventor
ブルゴワン－ヴォワラール，サンドリーヌ
マリー－ルイーズ レーマン，シルヴィア
ラチディ，ワリド
セーヴ，ミシェル
Original Assignee
ユニヴェルシテ グルノーブル アルプス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニヴェルシテ グルノーブル アルプス filed Critical ユニヴェルシテ グルノーブル アルプス
Publication of JP2020502498A publication Critical patent/JP2020502498A/ja
Publication of JP2020502498A5 publication Critical patent/JP2020502498A5/ja
Application granted granted Critical
Publication of JP7115756B2 publication Critical patent/JP7115756B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Cosmetics (AREA)
JP2019528092A 2016-11-25 2017-11-24 ヒトの皮膚の老化の新規バイオマーカー Expired - Fee Related JP7115756B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16306561.8 2016-11-25
EP16306561 2016-11-25
PCT/EP2017/080414 WO2018096117A1 (en) 2016-11-25 2017-11-24 New biomarkers of human skin aging

Publications (3)

Publication Number Publication Date
JP2020502498A JP2020502498A (ja) 2020-01-23
JP2020502498A5 JP2020502498A5 (https=) 2021-01-14
JP7115756B2 true JP7115756B2 (ja) 2022-08-09

Family

ID=57517827

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019528092A Expired - Fee Related JP7115756B2 (ja) 2016-11-25 2017-11-24 ヒトの皮膚の老化の新規バイオマーカー

Country Status (7)

Country Link
US (1) US20210109111A1 (https=)
EP (1) EP3545301A1 (https=)
JP (1) JP7115756B2 (https=)
CN (1) CN110268263B (https=)
CA (1) CA3041959A1 (https=)
RU (1) RU2019116069A (https=)
WO (1) WO2018096117A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190369119A1 (en) * 2018-06-04 2019-12-05 Avon Products, Inc. Protein Biomarkers for Identifying and Treating Aging Skin and Skin Conditions
JP7633003B2 (ja) * 2019-11-29 2025-02-19 ポーラ化成工業株式会社 抗老化成分のスクリーニング方法
WO2023090901A1 (ko) * 2021-11-18 2023-05-25 의료법인 성광의료재단 기계 학습을 이용한 세포 노화의 마커를 선별하는 방법, 세포 노화 바이오 마커, 및 이를 이용한 세놀리틱 제제를 스크리닝 하는 방법
KR20240146665A (ko) 2022-01-07 2024-10-08 오디티 랩스, 엘엘씨 피부 치료를 위한 조성물, 제제 및 방법
JP2023130972A (ja) * 2022-03-08 2023-09-21 株式会社 資生堂 黄ぐすみ抑制方法、黄ぐすみ抑制剤のスクリーニング方法、及び黄ぐすみ感受性の評価方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020012927A1 (en) 2000-03-10 2002-01-31 Burmer Glenna C. Nucleic acid sequences associated wih aging, particularly skin aging
WO2007023808A1 (ja) 2005-08-23 2007-03-01 Fancl Corporation 皮膚老化マーカーとその利用技術
WO2009048282A2 (en) 2007-10-09 2009-04-16 Amorepacific Corporation Method and kit for diagnosis of hormonal skin aging
US20120034613A1 (en) 2010-08-03 2012-02-09 Nse Products, Inc. Apparatus and Method for Testing Relationships Between Gene Expression and Physical Appearance of Skin
US20140163118A1 (en) 2011-05-03 2014-06-12 Dermachip Inc. Expression Signatures of Genes and Gene Networks Associated with Skin Aging

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10100121A1 (de) * 2001-01-03 2002-08-01 Henkel Kgaa Verfahren zur Bestimmung des Hautstreß oder der Hautalterung in vitro
EP1579221A2 (de) * 2003-01-03 2005-09-28 Alcedo Biotech GmbH Verwendungen von hmgb, hmgn, hmga proteinen
WO2004083398A2 (en) * 2003-03-17 2004-09-30 The Government Of The United States Of America As Represented By The Secretary Of Department Of Health And Human Services Therapeutic uses of hmgn1 and hmgn2
US8859021B2 (en) * 2007-05-14 2014-10-14 Sytheon Skin appearance through gene manipulation
FR2925313A1 (fr) * 2007-12-19 2009-06-26 Oreal Utilisation cosmetique de proteines de type plakoglobine
JP6336565B2 (ja) * 2013-03-15 2018-06-06 ザ プロクター アンド ギャンブル カンパニー 微生物からの自然防御の客観的尺度として皮膚から抗微生物ペプチドを測定するための非侵襲的方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020012927A1 (en) 2000-03-10 2002-01-31 Burmer Glenna C. Nucleic acid sequences associated wih aging, particularly skin aging
WO2007023808A1 (ja) 2005-08-23 2007-03-01 Fancl Corporation 皮膚老化マーカーとその利用技術
WO2009048282A2 (en) 2007-10-09 2009-04-16 Amorepacific Corporation Method and kit for diagnosis of hormonal skin aging
US20120034613A1 (en) 2010-08-03 2012-02-09 Nse Products, Inc. Apparatus and Method for Testing Relationships Between Gene Expression and Physical Appearance of Skin
US20140163118A1 (en) 2011-05-03 2014-06-12 Dermachip Inc. Expression Signatures of Genes and Gene Networks Associated with Skin Aging

Also Published As

Publication number Publication date
CN110268263B (zh) 2022-07-19
US20210109111A1 (en) 2021-04-15
CN110268263A (zh) 2019-09-20
WO2018096117A1 (en) 2018-05-31
JP2020502498A (ja) 2020-01-23
RU2019116069A (ru) 2020-12-25
CA3041959A1 (en) 2018-05-31
EP3545301A1 (en) 2019-10-02

Similar Documents

Publication Publication Date Title
JP7115756B2 (ja) ヒトの皮膚の老化の新規バイオマーカー
Kuehne et al. An integrative metabolomics and transcriptomics study to identify metabolic alterations in aged skin of humans in vivo
Gelfi et al. The human muscle proteome in aging
Insenser et al. A nontargeted proteomic approach to the study of visceral and subcutaneous adipose tissue in human obesity
JP5362219B2 (ja) 皮膚老化マーカーとその利用技術
Alfadda et al. Proteomic analysis of mature adipo cytes from obese patients in relation to aging
Kuppusamy et al. Proteins are potent biomarkers to detect colon cancer progression
Wawrusiewicz-Kurylonek et al. Increased maternal and cord blood betatrophin in gestational diabetes
JP2017038619A (ja) 皮膚老化を防止する物質をスクリーニングする方法
Li et al. Membrane proteomic analysis comparing squamous cell lung cancer tissue and tumour-adjacent normal tissue
EP3311176A2 (en) Role of citrullination in diagnosing diseases
CN103384830B (zh) Ide 作为用于头皮病症的生物标记的用途
Li et al. Identification of glia maturation factor beta as an independent prognostic predictor for serous ovarian cancer
Succoio et al. Proteomic analysis reveals novel common genes modulated in both replicative and stress-induced senescence
ES2568634T3 (es) Materiales y métodos para determinar el potencial de sensibilidad de compuestos
He et al. Placental proteome alterations in women with intrahepatic cholestasis of pregnancy
Park et al. Two-dimensional electrophoresis analyses of atopic dermatitis and the chances to detect new candidate proteins by the variations in immobilized pH gradient strips
Liang et al. The PCA and LDA analysis on the differential expression of proteins in breast cancer
Oumeraci et al. Bronchoalveolar lavage fluid of lung cancer patients: mapping the uncharted waters using proteomics technology
Yin et al. Analysis of the peptides detected in atopic dermatitis and various inflammatory diseases patients-derived sera
Liang et al. The differential expression of aqueous soluble proteins in breast normal and cancerous tissues in relation to ethnicity of the patients; Chinese, Malay and Indian
Takahashi et al. Mild caloric restriction up-regulates the expression of prohibitin: a proteome study
Fayez et al. New Insight in Etiology of Vitiligo, Association of IncRNA and some Immunological Parameters with Expression of Melanin Concentration Hormone and Sirtuin 1 Genes in Generalized and Segmented Vitiligo
Srihardyastutie et al. The proteomic analysis of pancreatic exocrine insufficiency protein marker in type 2 diabetes mellitus patients
Ritter et al. NRF2-mediated autophagic degradation of glycated vimentin in the skin by an elastin-derived peptide

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201120

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211020

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220426

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220621

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220721

R150 Certificate of patent or registration of utility model

Ref document number: 7115756

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees